Disclosures: Alberto Esquenazi, MD: Allergan (Products/Services: Yes) (Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Ipsen (Products/Services: Yes, No) (Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Merz (Products/Services: Yes) (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)

Objective: The aim of this ongoing observational study is to systematically assess goal attainment over 16 months in patients treated with ≥1 abobotulinumtoxinA (aboBoNT-A) injection(s) for lower-limb spasticity in routine clinical practice.

Design: AboLiSh is an ongoing prospective, longitudinal, observational study (NCT04050527) exploring the real-world utilization and effectiveness of aboBoNT-A for lower limb spasticity.Setting : International multicenter study.Participants : Adult patients (≥18 years old) with unilateral adult lower limb spasticity and able to take ≥5 steps (with or without assistance).

Interventions: Patients are treated with aboBoNT-A in accordance with local prescribing guidelines to achieve individualized treatment goals (participants and investigators set one primary goal and up to two secondary goals at baseline).

Main Outcome Measures: The primary endpoint is goal attainment as assessed using the cumulated (mean) GAS-leg T score, across all cycles for each subject.

Results: As of the 18th February 2021, 289 participants have been recruited; baseline characteristics for this cohort and their treatment goal categories are expected in the third quarter of 2021, and will be reported to the congress in the presentation of this research.Conclusions: Goals of lower-limb spasticity management include improving active and passive function, reducing pain and deformity, improving mobility, and facilitating concomitant treatments. Since the location and severity of spasticity may change over time or with treatment, patients need to be assessed repeatedly and management altered accordingly. The AboLiSh study will inform on goal setting and goal achievement in multiple treatment cycles for lower limb spasticity as well as help identify drivers influencing clinical decision making for these patients.

Level of Evidence: Level II

« Back to AAPM&R Annual Assembly 2021

PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/assessing-effectiveness-of-abobotulinumtoxina-injections-for-adult-lower-limb-spasticity-in-routine-clinical-practice-the-ongoing-abolish-study/